


Trigger Lock

Trigger Lock™ is a novel, proprietary and innovative delivery platform that enables the **controlled release of narcotic and opioid analgesics while deterring their abuse.**

A major problem faced by the industry is the growing abuse and misuse of its drugs by drug abusers, who extract the opioids from the drugs and achieve their immediate release. The proportion of narcotic/opioid analgesics abuse has more than tripled, from 6.8% in 1998 to 26.5% in 2008. Narcotic/opioid analgesics abuse continues to increase since current products remain easy to abuse.

Trigger Lock successfully addresses the issues of narcotic/opioid analgesics tampering:

- ✓ The sustained release microparticles are resistant to crushing: each microparticle retains its polymer coating which is virtually impervious to further crushing.
- ✓ Trigger Lock resists extraction attempts (even in boiling liquids) with beverages (alcoholic or not).
- ✓ Trigger Lock preserves the bioavailability of the compound.
- ✓ Trigger Lock is compatible with different dosage forms.



Opioid drug SR microparticles have been crushed with a mortar/pestle for two minutes and analyzed by sieving on 50-100-250 µm sieves.

FDA plans to implement a Risk Evaluation and Mitigation Strategy (REMS) requirement for all extended-release opioid analgesics. The FDA's move to restrict prescribing extended-release opioid analgesics should benefit tamper-resistant formulations such as **Trigger Lock-based formulations of opioids.**

Key Benefits of Trigger Lock

- 🔒 Micropump particles cannot be crushed to extract the narcotic/opioid analgesics;
- 🔒 Prevent misuse of scheduled drugs such as narcotic/opioid analgesics;
- 🔒 Additional modifications tailored to prevent other less publicized methods of foiling controlled release systems;
- 🔒 Provides either bioequivalent or improved pharmacokinetics to marketed narcotic/opioid analgesics; and,
- 🔒 May be applied to novel, already-marketed, or off-patent narcotic/opioids.



33 avenue du Dr. Georges Levy
69693 Vénissieux Cedex - France

Business Development Contact

Phone: +33 472 783 434

Fax: +33 472 783 435

E-mail: licensing@flamel.com

Flamel Technologies SA (NASDAQ: FLML) is a leading drug delivery company focused on the goal of developing safer, more efficacious formulations of drugs to tackle unmet medical needs. Its product development pipeline includes chemical and biological drugs formulated with its innovative and proprietary platforms, **Medusa®** and **Micropump®**. Several Medusa-based products are at various clinical stages of development. The Company has products approved in the USA and in Europe and manufactures Micropump-based products. Flamel Technologies has collaborations with a number of leading pharmaceutical and biotechnology companies. Additional information can be found at <http://www.flamel.com>.